The role of apoptosis in cancer development and treatment response

Nature Reviews Cancer

Volumn 5, Issue 3, 2005, Pages 231-237

  Brown, Martin ^a   Attardi, Laura D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; AUTOPHAGY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL AGING; CELL KILLING; CLONOGENIC ASSAY; DNA DAMAGE; DNA REPAIR; GENE MUTATION; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

APOPTOSIS; CELL DEATH; HUMANS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 14644407525     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1560     Document Type: Review

References (63)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Sarasin, A. An overview of the mechanisms of mutagenesis and carcinogenesis. Mutat. Res. 544, 93-106 (2003).
3. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
4. Vousden, K. H. & Lu, X. Live or let die: the cell's response to 053. Nature Rev. Cancer 2, 594-604 (2002).
5. Attardi, L. D. The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. Mutat. Res. 569, 145-157 (2005).
6. INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002).
7. Hall, E. J. Radiobiology for the Radiologist (J. B. Lippincott Company, Philadelphia, 2000).
8. waf1 in tumour response to radiation therapy. Oncogene 18, 6540-6545 (1999).
9. Koike, M. et al. Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice. Cancer Sci. 95, 541-546 (2004).
10. Fichtner, I. et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur. J. Cancer 40, 298-307 (2004).
11. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993).
12. Clarke, A. R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852 (1993).
13. Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993).
14. Lowe, S. W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
15. Weinstein, J. N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349 (1997).
16. Amundson, S. A. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101-6110 (2000).
17. Abend, M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int. J. Radiat. Biol. 79, 927-941 (2003).
18. Okada, H. & Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Rev. Cancer 4, 592-603 (2004).
19. Zong, W. X., Ditsworth, D., Bauer, D. E., Wang, Z. Q. & Thompson, C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 18, 1272-1282 (2004).
20. Chan, T. A., Hermeking, H., Lengauer, C., Kinzier, K. W. & Vogelstein, B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 401, 616-620 (1999).
21. Chu, K., Teele, N., Dewey, M. W., Albright, N. & Dewey, W. C. Computerized video time lapse study of cell cycle delay and arrest, mitotic catastrophe, apoptosis and clonogenic survival in irradiated 14-3-3σ and CDKN1A (p21) knockout cell lines. Radiat. Res. 162, 270-286 (2004).
22. Forrester, H. B., Albright, N., Ling, C. C. & Dewey, W. C. Computerized video time-lapse analysis of apoptosis of REC:Myc cells X-irradiated in different phases of the cell cycle. Radiat. Res. 154, 625-639 (2000).
23. Masters, J. R. & Koberle, B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nature Rev. Cancer 3, 517-525 (2003).
24. Taniguchi, T. et al. Disruption of the Fanconi anemia-BRCA pathway in cispiatin-sensltive ovarian tumors. Nature Med. 9, 568-574 (2003).
25. Gurubhagavatula, S. et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22, 2594-2601 (2004).
26. Endlich, B., Radford, I. R., Forrester, H. B. & Dewey, W. C. Computerized video time-lapse microscopy studies of ionizing radiation-induced rapid-interphase and mitosis-related apoptosis in lymphoid cells. Radiat. Res. 153, 36-48 (2000).
27. Puck, T. T. & Markus, P. I. Action of x-rays on mammalian cells. J. Exper. Med. 103, 653-666 (1956).
28. Reinhold, H. S. & De Bree, C. Tumour cure rate and cell survival of a transplantable rat rhabdomyosarcoma following x-irradiation. Eur. J. Cancer 4, 367-374 (1968).
29. Durand, R. E. Cure, regression and cell survival: a comparison of common radiobiological endpoints using an in vitro tumour model. Br. J. Radiol. 48, 556-571 (1975).
30. Teicher, B. A. in Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development (ed. Prendergast, G. C.) 7-40 (John Wiley and Sons, Hoboken, New Jersey, 2004).
31. Waldman, T. et al. Cell-cycle arrest versus cell death in cancer therapy. Nature Med. 3, 1034-1036 (1997).
32. Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res. 57, 4703-4706 (1997).
33. Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269 (1999).
34. Brown, J. M. NCI's anticancer drug screening program may not be selecting for clinically active compounds. Oncol. Res. 9, 213-215 (1997).
35. Ruth, A. C. & Roninson, I. B. Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res. 60, 2576-2578 (2000).
36. Brown, J. M. & Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 56, 1408-1416 (1998).
37. Schmitt, C. A., Rosenthal, C. T. & Lowe, S. W. Genetic analysis of chemoresistance in primary murine lymphomas. Nature Med. 6, 1023-1035 (2000).
38. Withers, H. R., Mason, K. A. & Thames, H. D. Jr. Late radiation response of kidney assayed by tubule-cell survival. Br. J. Radiol. 59, 587-595 (1986).
39. Tucker, S. L. et al. Direct analyses of in vivo colony survival after single and fractionated doses of radiation. Int. J. Radiat. Biol. 59, 777-795 (1991).
40. Hendry, J. H., Cai, W. B., Roberts, S. A. & Rotten, C. S. p53 deficiency sensitizes clonogenic cells to irradiation in the large but not the small intestine. Radiat. Res. 148, 254-259 (1997).
41. Potten, C. S. & Grant, H. K. The relationship between ionizing radiation-induced apoptosis and stem cells in the small and large intestine. Br. J. Cancer 78, 993-1003 (1998).
42. Komarova, E. A. et al. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16, 1391-1400 (1997).
43. Song, S. & Lambert, P. F. Different responses of epidermal and hair foilicular cells to radiation correlate with distinct patterns of p53 and p21 induction. Am. J. Pathol. 155, 1121-1127 (1999).
44. Gudkov, A. V. & Komarova, E. A. The role of p53 in determining sensitivity to radiotherapy. Nature Rev. Cancer 3, 117-129 (2003).
45. Held, K. D. Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis 2, 265-282 (1997).
46. Aldridge, D. R., Arends, M. J. & Radford, I. R. Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose-response. Br. J. Cancer 71, 571-577 (1995).
47. Man, J. W., Dionne, C. A., Kedersha, N. L. & Goldmacher, V. S. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Cancer Res. 57, 176-182 (1997).
48. Lock, R. B. & Stribinskiene, L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting cionogenic survival. Cancer Res. 56, 4006-4012 (1996).
49. Yin, D. X. & Schimke, R. T. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res. 55, 4922-4928 (1995).
50. Tannock, I. F. & Lee, C. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br. J. Cancer 84, 100-105 (2001).
51. Ekert, P. G. et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J. Cell Biol. 165, 835-842 (2004).
52. Westphal, C. H. et al. atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nature Genet. 16, 397-401 (1997).
53. Merritt, A. J., Allen, T. D., Potten, C. S. & Hickman, J. A. Apoptosis in small intestinal epithelial from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after γ-irradiation. Oncogene 14, 2759-2766 (1997).
54. Kemp, C. J., Sun, S. & Gurley, K. E. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res. 61, 327-332 (2001).
55. Ling, V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40 (Suppl.), 3-8 (1997).
56. Tannock, I. F. Tumor physiology and drug resistance. Cancer Metastasis Rev. 20, 123-132 (2001).
57. Townsend, D. M. & Tew, K. D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369-7375 (2003).
58. Brown, J. M. & Wilson, G. Apoptosis genes and resistance to cancer therapy: what do the experimental and clinical data tell us? Cancer Biol. Ther. 2, 477-490 (2003).
59. Altieri, D. C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7, 542-547 (2001).
60. Thames, H. D., Petersen, C., Petersen, S., Nieder, C. & Baumann, M. Immunohistochemicalty detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. Strahlenther. Onkol. 178, 411-121 (2002).
61. Schmitt, C. A. & Lowe, S. W. Apoptosis and therapy. J. Pathol. 187, 127-137 (1999).
62. Kovacs, M. S., Yudoh, K., Evans, J. W., Menke, D. & Brown, J. M. Stable translocations detected by fluorescence in situ hybridization: a rapid surrogate end point to evaluate the efficacy of a potentiator of tumor response to radiotherapy. Cancer Res. 57, 672-677 (1997).
63. Castedo, M. et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825-2837 (2004).